Quick Links

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from EMD Serono, Inc. and Pfizer, Inc.

Advances in™ Immuno-Oncology: Considerations for the Use of Checkpoint Inhibitors Across Solid Tumours

Release Date: November 9, 2018
Expiration Date: November 9, 2019
Media: Internet - based

Activity Overview

This activity, Advances in™ Immuno-Oncology: Considerations for the Use of Checkpoint Inhibitors Across Solid Tumours, will provide you with clinically important information about immune checkpoint inhibitors (ICPis) that you can use in the management of your patients with solid tumours. Listen to experts as they share clinical pearls regarding the incorporation of ICPis into their clinics. Topics will include the rationale for use of these agents, current and emerging strategies for selecting patients who can benefit from this approach, and placement of current data sets into the context of the treatment landscape. Moreover, you’ll learn about the identification, recognition, and management of immune-related toxicities. Start now to gain insights into this cutting-edge treatment approach.

Benefits of Completing Activity

Benefits of participating in the online activity, Advances in™ Immuno-Oncology: Considerations for the Use of Checkpoint Inhibitors Across Solid Tumours:

  • Enhanced understanding of why immune checkpoint inhibitors (ICPis) are clinically important across a wide range of tumour types
  • Improved competence of integrating ICPis into the management of your patients with solid tumours
  • Increased ability to incorporate appropriate strategies to mitigate immune-related adverse events associated with ICPis
  • Deepened knowledge of the clinical data sets supporting the use of ICPis, including in the management of brain metastases and as a part of combination approaches

Acknowledgement of Commercial Support

This activity is supported by educational grants from EMD Serono, Inc. and Pfizer, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational program is directed toward US & Ex-US medical oncologists, surgeons, pharmacists, physician assistants, and oncology nurses who treat or are involved in the treatment of patients with cancer.

Educational Objectives

Upon completion of this activity, you should be better prepared to:

  • Describe the rationale for the application of immunotherapeutic strategies to the management of solid tumors
  • Discuss biomarkers and patient characteristics which may be used to identify patients who may benefit from the use of a checkpoint inhibitor, or be eligible for clinical trials evaluating novel immunotherapeutic strategies
  • Apply clinical trial evidence to manage a variety of solid tumors in the context of evolving single-agent and combination immunotherapeutic strategies, including how these data may inform sequencing decisions
  • Utilize evidence from clinical trials and practical experience to proactively identify and mitigate the impact of immune-related adverse events (irAEs) among patients who receive immunotherapeutic approaches to treat their cancer

Faculty, Staff, and Planners' Disclosures


Caroline Robert, MD, PhD
Head, Dermatology Unit
Department of Medicine
Gustave Roussy and Paris Sud University
Villejuif Grand-Paris, France

Disclosure: Consultant/Advisory Boards: Bristol-Myers Squibb, Novartis, Roche, Amgen, Merck, Pierre Fabre

Laurence Albiges, MD, PhD
Head, Genito-urinary Tumor Unit
Department of Cancer Medicine
Gustave Roussy
Villejuif Grand-Paris, France

Disclosure: Advisory Board: Novartis, Amgen, Bristol-Myers Squibb, Ipsen, Roche, Pfizer, Astellas, Merck

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By